Non-posttransplant lymphoproliferative disorder malignancy after hematopoietic stem cell transplantation in patients with primary immunodeficiency: UK experience.

Mohamed Najib Mohamed Unni,Reem Elfeky,Kanchan Rao,Zohreh Nademi,Robert Chiesa,Persis Amrolia,Roderick Skinner,Olga Slater,Austen Worth,Terence Flood,Mario Abinun,Sophie Hambleton,Waseem Qasim,Hubert B Gaspar,Andrew J Cant,Andrew R Gennery,Paul Veys,Mary A Slatter

The Journal of allergy and clinical immunology（2018）

引用 5|浏览16

暂无评分

摘要

Secondary malignancy post haematopoietic stem cell transplantation (HSCT) for malignant disorders is well recognized. There are very few published reports on malignancy post HSCT for Primary Immunodeficiency (PID). We report 12 cases of 944 patients, who developed non-PTLD malignancy post-HSCT for PID.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要